Navigation Links
Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations
Date:10/28/2010

demarks of International Technidyne Corporation.

Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2010 financial results or future performance, contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address issues raised by FDA inspections adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's m
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... financial results after the market closes on Tuesday, August ... conference call the same day at 4:30 p.m. ET ... provide a corporate update. The live call ...
(Date:7/28/2015)...  Champions Oncology, Inc. (OTC: CSBR), engaged in the ... the development and use of oncology drugs, today announced ... 2015. Fourth Quarter and Recent Business Highlights: ... prior year period result , Procured a quarterly ... Joel Ackerman, Champions Oncology CEO, stated, "The end of ...
(Date:7/28/2015)... July 28, 2015  Cepheid (Nasdaq: CPHD ... and portable clinical molecular diagnostic system designed to ... market.  At just 9 inches tall, and weighing ... the same high quality PCR-based Xpert® cartridges as ... accurate clinical molecular diagnostic tests to be performed ...
Breaking Medicine Technology:Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4
... Expand Testing Using Cellular ... Antioxidant Activity Assay, ... with the release of results from a new study,showing Wild ... red grapes and strawberries in an expanded,test using the Cellular ...
... Oct. 8 Vical Incorporated (Nasdaq: VICL ... nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant may ... vaccines and,peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., ... present the data today,Wednesday, October 8, at the ...
Cached Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5
(Date:7/28/2015)... , ... July 28, 2015 , ... Healthpointe ’s ... that returns skin to a smooth state, and reduces the appearance of fine lines ... and only FDA-approved injectable gel to instantly add volume to your cheek area to ...
(Date:7/28/2015)... ... July 28, 2015 , ... According to WFTV on ... the lead among heroin toxicity cases. According to recent statistic Orlando suffers at least ... known as a hub of heroin, and law enforcement officials are struggling to keep ...
(Date:7/28/2015)... ... July 28, 2015 , ... BiologicsMD, Inc. , ... for the treatment of bone disorders and conditions of hair loss, announced that ... Proteins of Collagen Binding-Domain and Parathyroid Hormone". The issued patent claims methods of ...
(Date:7/28/2015)... ... 2015 , ... Women fear developing Alzheimer's disease more than having a heart ... stroke are treatable, but there is little an individual can do to arrest the ... a clinical trial, reports the July 2015 Harvard Women's Health Watch . , ...
(Date:7/28/2015)... Angeles, CA (PRWEB) , ... July 28, 2015 ... ... Sports entitled "A Breakdown of Mets' David Wright's Spinal Stenosis Injury" discussed ... the field. Wright’s spinal stenosis is acquired lumbar stenosis, brought on by degenerative ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3
... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
... was announced that the,U.S. Court of Federal Claims ... favor of a child who regressed into autism ... the mercury-based preservative,thimerosal., Case documents state that ... underlying condition that ultimately led to,regressive encephalopathy and ...
... the University of Minnesota and North Carolina State University ... friendship and companionship they also share the same ... the researchers say that because of the way the ... some humans and dogs. , Jaime Modiano, V.M.D., Ph.D., ...
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Blue Cross and Blue,Shield,s Member Health Index has ... of the Blue Cross and Blue Shield Association, ... Shield companies are,working to increase the efficiency and ... Department of Health Care Policy,evaluates submissions from participating ...
... the full line of dermatologist endorsed moisturizers, ... the,makers of a full line of dermatologist endorsed ... skin conditions, is launching its 2008,"Prepare to Unveil ... looking and beautiful skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, ...
Cached Medicine News:Health News:Population Health Impact Institute Announces New Board Members 2Health News:Government Concludes Vaccines Caused Autism 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 3Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4
... critical patients more waveforms, 12-Lead ECG, ... package and cardiac output bundled into ... with your patients., We use quick-action ... which means less time spent looking,through ...
... comfort. The Nylon Finger Trap are gentle on ... Nylon Finger Traps create a complete upper extremity ... Digi Grip or ISI Advanced Universal K Table. ... packs and come in five sizes: Extra-small, small, ...
... FH system uses a ... infrastructure operating in ... communication of patient information. ... of up to 640 ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
Medicine Products: